1This resource was developed by a Task Force appointed by ASAM’s Executive Council. To enable more rapid development and dissemination it was not developed through ASAM’s normal process for clinical guidance development that is overseen by the ASAM Quality Improvement Council.
2 https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-breastfeeding.html (accessed 4/24/2020)
3 Rates of Maternal and Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review. Huntley BJF, Huntley ES, Di Mascio D, Chen T, Berghella V, Chauhan SP Obstet Gynecol. 2020.
4 https://www.cdc.gov/mmwr/volumes/69/wr/mm6925a1.html (accessed 7-19-20)
5 https://www.rcog.org.uk/globalassets/documents/guidelines/2020-04-17-coronavirus-covid-19-infection-in-pregnancy.pdf (accessed 4/23/2020).
6
6Rates of Maternal and Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2 Infection: A Systematic Review. Huntley BJF, Huntley ES, Di Mascio D, Chen T, Berghella V, Chauhan SP Obstet Gynecol. 2020
7 Transplacental transmission of SARS-CoV-2 infection. Alexandre J. Vivanti, Christelle Vauloup-Fellous, Sophie Prevot, Veronique Zupan, Cecile Suffee, Jeremy Do Cao, Alexandra Benachi & Daniele De Luca Nature Communications volume 11, Article number: 3572 (2020).
https://www.nature.com/articles/s41467-020-17436-6
8 https://www.cdc.gov/coronavirus/2019-ncov/hcp/inpatient-obstetric-healthcare-guidance.html
9 https://www.who.int/news-room/q-a-detail/q-a-on-covid-19-and-breastfeeding
10 https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-breastfeeding.html (accessed 4/24/2020).
11 https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/breastfeeding-guidance-post-hospital-discharge/
12 https://www.acf.hhs.gov/cb/resource/covid-19-resources
CONTENT DISCLAIMER
This Clinical Guidance (“Guidance”) is provided for informational and educational purposes only. It is intended to provide practical clinical guidance to ad- diction medicine physicians and others caring for individuals with substance use disorders during the COVID-19 pandemic as it unfolds. Adherence to any recommendations included in this Guidance will not ensure successful treatment in every situation. Furthermore, the recommendations contained in this Guidance should not be interpreted as setting a standard of care or be deemed inclusive of all proper methods of care nor exclusive of other methods of care reasonably directed to obtaining the same results.
The ultimate judgment regarding the propriety of any specific therapy must be made by the physician and the patient in light of all the circumstances pre- sented by the individual patient, and the known variability and biological behavior of the medical condition.
This Guidance and its conclusions and recommendations reflect the best available information at the time the Guidance was prepared. The results of future studies may require revisions to the recommendations in this Guidance to reflect new data.
ASAM does not warrant the accuracy or completeness of the Guidance and assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this Guidance or for any errors or omissions.